ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2025 17:42:06 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

29 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

28 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

09 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jan 2025 16:53:30 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Key Management Appointments

12 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Dec 2024 16:35:10 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

13 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 19:04:44 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2024 16:40:50 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

09 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2024 18:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2024 18:00:47 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2024 18:00:55 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

23 May 2024 17:01:39 By Nasdaq GlobeNewswire